- Home
- SEVN vs NTHI Comparison
SEVN vs NTHI Comparison
Compare SEVN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- NTHI
- Stock Information
- Founded
- SEVN 1986
- NTHI 2008
- Country
- SEVN United States
- NTHI United States
- Employees
- SEVN N/A
- NTHI N/A
- Industry
- SEVN Real Estate Investment Trusts
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- NTHI Health Care
- Exchange
- SEVN Nasdaq
- NTHI Nasdaq
- Market Cap
- SEVN 173.7M
- NTHI 142.5M
- IPO Year
- SEVN N/A
- NTHI N/A
- Fundamental
- Price
- SEVN $11.86
- NTHI $7.39
- Analyst Decision
- SEVN Strong Buy
- NTHI
- Analyst Count
- SEVN 4
- NTHI 0
- Target Price
- SEVN $14.50
- NTHI N/A
- AVG Volume (30 Days)
- SEVN 36.2K
- NTHI 93.9K
- Earning Date
- SEVN 07-28-2025
- NTHI 01-01-0001
- Dividend Yield
- SEVN 11.90%
- NTHI N/A
- EPS Growth
- SEVN N/A
- NTHI N/A
- EPS
- SEVN 1.15
- NTHI N/A
- Revenue
- SEVN $30,074,000.00
- NTHI $79,990.00
- Revenue This Year
- SEVN $14.81
- NTHI N/A
- Revenue Next Year
- SEVN $2.73
- NTHI N/A
- P/E Ratio
- SEVN $10.23
- NTHI N/A
- Revenue Growth
- SEVN N/A
- NTHI 13.52
- 52 Week Low
- SEVN $10.18
- NTHI $4.11
- 52 Week High
- SEVN $14.66
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SEVN 51.68
- NTHI N/A
- Support Level
- SEVN $11.40
- NTHI N/A
- Resistance Level
- SEVN $11.99
- NTHI N/A
- Average True Range (ATR)
- SEVN 0.39
- NTHI 0.00
- MACD
- SEVN 0.00
- NTHI 0.00
- Stochastic Oscillator
- SEVN 49.46
- NTHI 0.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").